<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097680</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2013/912</org_study_id>
    <secondary_id>2013-002964-22</secondary_id>
    <nct_id>NCT02097680</nct_id>
  </id_info>
  <brief_title>Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men</brief_title>
  <acronym>HEPAROB</acronym>
  <official_title>Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It seems plausible that increased aromatase activity in obese men, as a result of a larger
      fat mass, is responsible for decreased levels of testosterone. Therefore aromatase inhibition
      increases testosterone levels, which may affect hepatic and cardiac function.

      In this intervention study two groups of hypogonadal obese men are compared. Group A is
      treated with Letrozole 2.5 mg (aromatase inhibitor) once every two days during four months; a
      group with normal testosterone and low oestrogen concentrations. Group B is treated with
      placebo once every two days during four months; this group will retain low testosterone - and
      high oestrogenic concentrations.

      The primary objective of the study is to evaluate effects of changed sex steroids in obese
      men on hepatic and cardiac function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac function parameters</measure>
    <time_frame>after 4 months intervention</time_frame>
    <description>heart function will be measured by echocardiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic function parameters</measure>
    <time_frame>before intervention</time_frame>
    <description>Baseline sex steroids will be measured by Liquid chromatography-mass spectrometry (LC-MS/MS) in fasting blood samples, before 10:00 am. Liver function will be analysed by a Nuclear Magnetic Resonance (NMR) recording</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic function parameters</measure>
    <time_frame>after 4 months intervention</time_frame>
    <description>Baseline sex steroids will be measured by Liquid chromatography-mass spectrometry (LC-MS/MS) in fasting blood samples, before 10:00 am. Liver function will be analysed by a Nuclear Magnetic Resonance (NMR) recording</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac function parameters</measure>
    <time_frame>before intervention</time_frame>
    <description>heart function will be measured by echocardiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>glucose metabolism</measure>
    <time_frame>Before four months intervention.</time_frame>
    <description>Glucose metabolism will be estimated by an oral glucose tolerance test (OGTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>Before intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>after four months intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose metabolism</measure>
    <time_frame>Before intervention.</time_frame>
    <description>Glucose metabolism will be estimated by an oral glucose tolerance test (OGTT).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>One Letrozole 2.5 mg capsule every two days during four months</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One placebo capsule every two days during four months</description>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese male subjects

          -  Planned for gastric bypass (BMI &gt; 30 kg/mÂ²)

          -  low testosterone levels

          -  age between 20 and 65

        Exclusion Criteria:

          -  Primary hypogonadism or secondary hypogonadism due to genetic causes (Kallman syndrome
             etc.), tumours, infiltrative diseases, infections, pituitary apoplexy, trauma,
             critical illness, chronic systemic illness or intentional.

          -  Treatment with corticoids, opiates (on a daily basis), androgen- or estrogen analogs
             or CYP2A6 substrates (Dexmedetomidine, Ifosfamide, Methoxsalen, Miconazole,
             Tranylcypromine).

          -  Impaired renal function defined as serum-creatine &gt; 1.5 mg/dL

          -  Clinically significant active cardiovascular disease including history of myocardial
             infarction within the past 6 months and/or heart failure (NYHA class III or IV) at the
             discretion of the investigator

          -  Cancer or any clinically significant disease or disorder, which in the investigator's
             opinion could interfere with the results of the trial

          -  Palpable prostate nodule or induration, Prostate-specific antigen (PSA) &gt; 3 ng/mL,
             prostatism, untreated sleep apnea syndrome, erythrocytosis (hematocrit &gt; 50%) or
             hyperviscosity. (cfr. Endocrine Society Clinical Practice Guideline by Bhasin S et
             al.)

          -  Known or suspected abuse of alcohol or narcotics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Ruige, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Ruige, MD, PhD</last_name>
    <email>johannes.ruige@ugent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marlies Bekaert</last_name>
    <phone>09/3323441</phone>
    <email>marlies.bekaert@ugent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yves Van Nieuwenhove, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Ruige, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Smeets, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tine De Backer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marlies Bekaert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>with disturbed glucose metabolism</keyword>
  <keyword>without disturbed glucose metabolism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

